Skip to main content
. 2023 Jul 28;32:100690. doi: 10.1016/j.lanepe.2023.100690

Fig. 3.

Fig. 3

Change in body mass index. Changes over time before and after initiation of elexacaftor/tezacaftor/ivacaftor (ETI) therapy (left panels) and changes in severity category from the year before to the year after initiation of ETI therapy (right panels) for adults (A) and adolescents (B). BMI, body mass index; pwCF, people with cystic fibrosis.